Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted first-quarter revenues of $11.9 billion, beating the consensus of $11.5 billion, an increase of 5% year-over-year, or 6% when adjusted for foreign exchange impacts, primarily driven by Eliquis, Reblozyl, and Opdualag, partially offset by Opdivo and Revlimid. Growth Portfolio worldwide revenues increased to $4.8 billion, up 8% or 11% when adjusted for foreign exchange impacts. This increase was primarily driven by higher demand for Reblozyl, O